Zofia Piotrowska

13PUBLICATIONS

141CO-AUTHORS

Molecular targetsPredictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)

Get your video featured.

Publish with JoVE

Get your video featured.

Publish with JoVE

Publications (13)

Sort by Publication Date:

|Jul 13, 2026

Osimertinib Plus Gefitinib in Patients with EGFR-Mutated Advanced Non-Small Cell Lung Cancer and EGFR (C797X) Mutation Following First-Line Osimertinib: ORCHARD.

|May 13, 2026

BLU-451, a CNS-Active, Potent, and Selective Small-Molecule Inhibitor Against Uncommon EGFR Mutations.

|Mar 06, 2026

ELIOS: A Multicenter, Molecular Profiling Study of Patients with EGFR-Mutant Advanced Non-Small Cell Lung Cancer Treated with First-Line Osimertinib.

Zofia Piotrowska, Myung-Ju Ahn, Pei Jye Voon

|Mar 06, 2026

Genomic Profiling of Epidermal Growth Factor Receptor Mutation-Positive Non-Small Cell Lung Cancer Post-Progression on First-Line Osimertinib: Phase II ORCHARD Study.

Helena A Yu, Kwan Ho Tang, Aleksandra A Markovets

|Dec 17, 2025

Reply to: Blind Spots in REZILIENT-1: Does Post-Platinum Zipalertinib Address Needs in Epidermal Growth Factor Receptor ex20ins+ Non-Small Cell Lung Cancer?

Zofia Piotrowska, Helena A Yu

|Jun 04, 2025

ORCHARD: Osimertinib Plus Necitumumab in Patients With Epidermal Growth Factor Receptor-Mutated Advanced Non-Small Cell Lung Cancer With a Secondary Epidermal Growth Factor Receptor Alteration Whose Disease Had Progressed on First-Line Osimertinib.

Jonathan W Riess, Adrianus J de Langen, Santiago Ponce

Pageof 3

Frequent Collaborators

Helena Alexandra Yu

Xiuning Le

Byoung Chul Cho

Kwan Ho Tang

Sarah B Goldberg

Adrianus Johannes De Langen

Alexander I Spira

Jonathan W Riess

Danny Nguyen

Jonathan W Goldman

Frequent Collaborators

Helena Alexandra Yu

Xiuning Le

Byoung Chul Cho

Kwan Ho Tang